San Diego-based clinical-stage drug developer ADARx Pharmaceuticals has raised $446.3 million in an upsized U.S. Initial Public Offering, illustrating resilient institutional demand for late-stage biotech assets.
Key Offering Metrics & Strategic Backing:
- Upsized IPO Details: Sold 26.3 million shares at $17.00 per share (the top of its marketed range), expanding from its initial target of 21.9 million shares.
- Corporate Backing: Global pharma giant AbbVie agreed to invest up to $100 million via a concurrent private placement, acquiring a ~4.9% equity stake post-IPO.
- Clinical Lead Candidate: Proceeds will advance onvuzosiran, an advanced RNA-targeted therapeutic currently in late-stage clinical trials for hereditary angioedema (a rare genetic disorder).
- Underwriters & Ticker: Bookrunners include J.P. Morgan, Morgan Stanley, and TD Cowen. Trading begins on the Nasdaq under the ticker ADRX.
- Broader Sector Momentum: Follows Electra Therapeutics’ $350 million upsized IPO, alongside new listing filings from City Therapeutics, Iambic Therapeutics, Retension Pharmaceuticals, and TRexBio, as investors seek insulation from broader geopolitical and AI-driven market shifts.
A major biotech milestone highlighting strong capital market appetite for high-potential RNA platforms and late-stage clinical pipelines! 📊🔬🇺🇸